Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23948853 | 0.92 | PDCD1 (0.87) | PDCD1CD274 | |
| SCHEMBL24613351 | 0.80 | CD274 (0.69) | PDCD1CD274 | |
| SCHEMBL23949090 | 0.76 | CD274 (0.63) | PDCD1CD274 | |
| SCHEMBL23949622 | 0.76 | CD274 (0.63) | PDCD1CD274 | |
| SCHEMBL24613070 | 0.76 | CD274 (0.63) | PDCD1CD274 | |
| SCHEMBL23949406 | 0.75 | CD274 (0.62) | PDCD1CD274 | |
| SCHEMBL24613076 | 0.75 | CD274 (0.62) | PDCD1CD274 | |
| SCHEMBL18760991 | 0.74 | CD274 (0.66) | PDCD1CD274 | |
| SCHEMBL24613071 | 0.74 | CD274 (0.61) | PDCD1CD274 | |
| SCHEMBL23949450 | 0.74 | CD274 (0.61) | PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | PDCD1 2/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.